EP Patent

EP4126237B1 — Dimaleate form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea

Assigned to Lek Pharmaceuticals dd · Expires 2024-04-10 · 2y expired

What this patent protects

Patent listed against Daurismo.

Drugs covered by this patent

Patent Metadata

Patent number
EP4126237B1
Jurisdiction
EP
Classification
—
Expires
2024-04-10
Drug substance claim
No
Drug product claim
No
Assignee
Lek Pharmaceuticals dd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.